Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046300 | 0.95 | CA12 (0.36) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL19204194 | 0.95 | CA12 (0.36) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL409603 | 0.89 | CA12 (0.40) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL10046503 | 0.87 | CA12 (0.35) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL15712065 | 0.87 | CA12 (0.35) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL15712078 | 0.87 | CA12 (0.35) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL19579307 | 0.85 | CA12 (0.36) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL409105 | 0.84 | CA12 (0.37) | CA12CA2CA14TDP1MAOA | |
| SCHEMBL19579098 | 0.81 | MEN1 (0.35) | CA12CA2CA14MEN1KMT2A | |
| SCHEMBL19446137 | 0.81 | CA12 (0.36) | CA12CA2CA14TDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669084-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2014-03-11 | — | — | US | disclosed |
| US-20120021430-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021430-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, SGMS1 | CA12 205/4885CA2 1281/4885CA14 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.